



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Liraglutide-¹³C₅,¹⁵N TFA

Cat. No.:	HY-P0014S1
Molecular Formula:	C ₁₆₇ ¹³ C ₅ H ₂₆₅ N ₄₂ ¹⁵ NO ₅₁ ·x C ₂ HF ₃ O ₂
Sequence:	His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-{Val-13C ₅ ,15N}-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-[Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (TFA salt) N6-[N-(1-oxohexadecyl)-L-γ-glutamyl] HAEGTFTSDV SSYLEGQAAK EFIGLWVRGR G (TFA salt)
Sequence Shortening:	HAEGTFTSD-{Val-13C ₅ ,15N}-SSYLQAA-{Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]}-EFIGLWVRGRG (TFA salt)
Target:	Isotope-Labeled Compounds; GLP Receptor; GCGR
Pathway:	Others; GPCR/G Protein
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 1 mg/mL (adjust pH to 10 with NH ₃ ·H ₂ O)
----------	---

BIOLOGICAL ACTIVITY

Description	Liraglutide- ¹³ C ₅ , ¹⁵ N (tetraTFA) is the ¹³ C and ¹⁵ N labeled Liraglutide (HY-P0014) ^[1] . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus ^[2] .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA